Background: Evidence suggests that cytokines (IL-6) and alteration of the hypothalamic—pituitary—adrenal (HPA) axis play a crucial role in the etiology of depression. Patients with cancer show elevated prevalence rates for depression. The objective of this cross-sectional study was to investigate the associations between these abnormalities and depression. Methods: Plasma concentrations of IL-6 and cortisol were measured in cancer patients with (N = 31) and without depression (N = 83). The relative diurnal variation of cortisol (cortisol VAR), expressed in percentage, was calculated. Results: There was a significant difference in median plasma concentration of IL-6 between the patients with depression and those without (18.7 vs 2.7 pg/mL; P < .001). Relative cortisol VAR was decreased in depressed patients as compared with patients without depression (11.72% vs 60.6%, P = .037). A positive correlation between the depressive symptoms and IL-6 concentration was found (r = 0.469, P < .001). Negative correlations were found between cortisol VAR versus depressive symptoms and cortisol VAR versus IL-6 (r = -0.6, P < .001 and r = -0.52, P < .001, respectively). IL-6 (odds ratio [OR] = 1.1; 95% confidence interval [CI] = 1.0-1.2; P = .006) and cortisol VAR (OR = 1.3; 95%CI = 1.0-1.4; P = .02) are independently associated with depression. Conclusions: Depression in cancer is associated with increased plasma IL-6 concentrations and dysfunction of the HPA axis.
Hotopf M., Chidgey J., Addington-Hall J., Ly KLDepression in advanced disease: a systematic review. Part 1. Prevalence and case finding. Palliat Med. 2002;16:81-97.
2.
Katon W., Sullivan MDDepression and chronic medical illness. J Clin Psychiatry . 1990;51(Suppl 6):3-11.
3.
McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CBDepression in patients with cancer. Arch Gen Psychiatry . 1995;52:89-99.
4.
Nemeroff C., Widerlöv E., Bissette G.Elevated cerebrospinal fluid concentrations of corticotropin-releasing factor-like immunoreactivity in major depression. Science . 1984;226: 1342-1344.
5.
Deuschle M., Schweiger U., Weber B., et al. Diurnal activity and pulsatiliy of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab. 1997;82:234-238.
6.
Holsboer F., von Bardeleben U., Wiedemann K., Muller OA, Stalla GKSerial assessment of corticotropin-releasing hormone response after dexamethason in depression. Implications for pathophysiology of DST nonsuppression . Biol Psychiatry. 1987;22:228-234.
7.
Heuser I., Yassouridis A., Holsboer F.The combined dexamethason/CRH test: a refined laboratory test for psychiatric disorder. J Psychiatr Res. 1994 ;28:341-356.
8.
Danzer R., Bluthke RM, Kent S., Goddall G.Behavioral effects of cytokines: an insight into mechanisms of sickness behavior . Methods Neurosci. 1993;17:130-144.
9.
Van Deventer SJH , Buller HR, ten Carte JW, Aarden LA, Hack CE, Sturk A.Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibirinolytic, and complement pathways . Blood. 1990;76:2520-2526.
10.
Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GPThe pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998;128:127-137.
11.
Vuoristo MS , Kellokumpu-Lehtinen P., Laine S., et al. The value of serum S-100beta and interleukins as tumor markers in advanced melanoma . Melanoma Res. 2000;10:237-241.
12.
Breuninger LM, Dempsey WL, Uhl J., Murasko DMHydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes . Clin Immunol Immunopathol . 1993;69:205-214.
13.
Papanicolaou DA, Petrides JS, Tsigos C., et al. Exercise stimulates interleukin-6 secretion: Inhibition by glucocorticoids and correlation with catecholamines . Am J Physiol. 1996;271: E601-E605.
14.
Mastorakos G., Chrousos GP, Weber JSRecombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993 ;77:1690-1694.
15.
Besedovsky HO, Del Rey A.Immune-neuro-endocrine interaction: facts and hypotheses. Endocr Rev. 1996;17:64-102.
16.
Jehn CF, Kuehnhardt D., Bartholomae A., et al. Biomarkers of depression in cancer patients with depression . Cancer. 2006; 107:2723-2729.
17.
Karnofsky DA , Burchenal JHThe clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents. New York, NY: Columbia University Press; 1949 :191.
18.
Herrmann C.International experiences with the Hospital Anxiety and Depression Scale: a review of validation data and clinical results . J Psychosom Res. 1997;42:17-41.
Moorey S., Greer S., Watson M.The factor structure and factor stability of the Hospital Anxiety and Depression Scale in patients with cancer. Br J Psychiatry . 1991;158:255-259.
21.
First MB, Spitzer RL, Gibbon M., Williams JBW.Structured Clinical Interview for DSM-IV Axis I Disorders. Research Version, Patient Edition. New York, NY: Biometrics Research, New York State Psychiatric Institute; 1999.
22.
American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
23.
Musselman DL , Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry . 2001; 158:1252-1257.
24.
Sluzewska A. , Rybakowski J., Bosmans E., et al. Indicators of immune activation in major depression. Psychiatry Res. 1996; 64:161-167.
25.
Miller AH, Pariante CM, Pearce BDEffects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999;461:107-116.
26.
Massie MJ, Holland JCThe cancer patient with pain: psychiatric complication and their management . Med Clin North Am. 1987;71:243-258.
27.
Peteet J., Tay V., Choen G., MacIntyre J.Pain characteristics and treatment in an outpatient cancer population . Cancer. 1986; 57:1259-1265.
28.
Spiegel D., Sand S., Koopman C.Pain and depression in patients with cancer. Cancer . 1994;74:2570-2578.
29.
Kathol RG, Mutigi A., Williams J., Clamon G., Noyes R.Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry. 1990;147:1021-1024.
30.
Cohen-Cole SA , Brown FW, McDaniel JSDiagnostic assessment of depression in the medically ill. In: Stoudemire A, Fogel B, eds. Psychiatric Care of the Medical Patient. New York, NY: Oxford University Press;1993:53-70.
31.
Härter M., Woll S.Screening for mental disorders in cancer, cardiovascular and musculoskeletal disease. Soc. Psychiatr Epidemiol. 2006;41:56-62.
32.
Dickens C., McGowan L., Clark-Carter D., Creed F.Depression in rheumatoid arthritis: a systemic review of the literature with meta-analysis. Psychosom Med. 2002;64:52-60.
33.
Lesperance F., Frasure-Smith N.Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000; 48:379-391.
Zorilla EP, Luborsky L., McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199-226.
36.
Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C., Malarkey WB, Glaser R.Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci U S A. 2003;100:9090-9095.
37.
DeRijk RH, Boelen A., Tilders FJ, Berkenbosch F.Induction of plasma interleukin-6 by circulating adrenaline in the rat. Psychoneuroendocrinology. 1994;19:155-163.
38.
Modell S., Lauer CJ, Schreiber W., Huber J., Krieg JC, Holsboer F.Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology. 1998;18:253-262.
